DDX41 and Autoimmunity: In a review of CASPR2 and LGI1 autoimmunity in pediatric patients, 37.8% (14/37) patients had anti-LGI1 Abs, 37.8% (14/37) had anti-CASPR2 Abs, and 24.3% (9/37) patients were double-positive for anti-LGI1 and anti-CASPR2 Abs (Nosadini et al., 2019).